Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Omics-based Predictors of NAFLD/Potential NASH: A New Era Towards Valid and Reliable Non-invasive Diagnosis and Personalized Therapy

NCT05301231 is registered in ClinicalTrials.gov with National Research Centre, Egypt as lead sponsor.

NCT NCT05301231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05301231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Omics-based Predictors of NAFLD/Potential NASH: A New Era Towards Valid and Reliable Non-invasive Diagnosis and Personalized Therapy
Lead sponsor
National Research Centre, Egypt
Phase
Observational
Overall status
Unknown status
Start date
August 1, 2022
Completion date
April 30, 2024
Enrollment
450 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non alcoholic steatohepatitis, non-alcoholic fatty liver disease